Prime Minster Shri. Narendra Modi’s visit to Bharat Biotech today, was a momentous occasion. In a statement from Bharat Biotech said “We are humbled by the visit of Prime Minister Shri. Narendra Modi Ji to the Bharat Biotech manufacturing facility in Genome Valley, Hyderabad today.”
At the Bharat Biotech facility in Hyderabad, was briefed about their indigenous COVID-19 vaccine. Congratulated the scientists for their progress in the trials so far. Their team is closely working with ICMR to facilitate speedy progress. pic.twitter.com/C6kkfKQlbl
— Narendra Modi (@narendramodi) November 28, 2020
“Bharat Biotech is a leader in pandemic vaccines and we are truly honoured by this recognition”
The prime minister’s visit serves as a great inspiration to our team, and further reinforces our commitment towards scientific discovery, solving public health issues, and the nation’s fight against COVID-19.
COVAXIN™ India’s first indigenous vaccine with the Phase 3 clinical trial underway, is the first, largest, and the ONLY efficacy trial in the developing world, involving a large number of volunteers across 25 sites.
The COVAXIN™ phase III trial is being conducted across India in 26,000 participants. The vaccine will be produced in the only-of-its-kind Biosafety Level 3 production facility in the world.
An extremely memorable day for Bharat Biotech to have Hon’ble Prime Minister of India, Shri PM Narendra Modi, visit our campus. He commended BBIL’s efforts towards COVAXIN and congratulated the progress COVAXINᵀᴹ thus far. pic.twitter.com/Dy1VQhdZl0
— BharatBiotech (@BharatBiotech) November 28, 2020
We take this opportunity to thank the Government of India, Regulators, our vaccine development partners, medical fraternity, medical investigators including hospitals for their relentless assistance and cooperation in the development of vaccines, also phase 3 clinical trials for COVAXIN™.
We greatly appreciate every volunteer who has come forward for the trial thus far and we thank you for your service to the nation. Bharat reiterates our commitment towards developing a safe and efficacious vaccine for all.
